A detailed history of Bank Of America Corp transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 59,539 shares of AVIR stock, worth $189,929. This represents 0.0% of its overall portfolio holdings.

Number of Shares
59,539
Previous 69,477 14.3%
Holding current value
$189,929
Previous $229,000 13.1%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.17 - $4.02 $31,503 - $39,950
-9,938 Reduced 14.3%
59,539 $199,000
Q2 2024

Aug 14, 2024

BUY
$3.31 - $4.04 $7,980 - $9,740
2,411 Added 3.59%
69,477 $229,000
Q1 2024

May 15, 2024

SELL
$3.09 - $4.56 $545,873 - $805,560
-176,658 Reduced 72.48%
67,066 $270,000
Q4 2023

Feb 14, 2024

BUY
$2.8 - $3.35 $395,399 - $473,066
141,214 Added 137.76%
243,724 $743,000
Q2 2023

Aug 14, 2023

SELL
$3.21 - $5.06 $109,181 - $172,105
-34,013 Reduced 24.91%
102,510 $383,000
Q1 2023

May 12, 2023

SELL
$3.0 - $4.97 $113,469 - $187,980
-37,823 Reduced 21.69%
136,523 $457,000
Q4 2022

Feb 10, 2023

BUY
$4.35 - $6.17 $199,521 - $282,999
45,867 Added 35.7%
174,346 $838,000
Q3 2022

Nov 14, 2022

BUY
$5.49 - $8.79 $456,910 - $731,556
83,226 Added 183.91%
128,479 $731,000
Q2 2022

Aug 12, 2022

BUY
$5.33 - $8.18 $41,254 - $63,313
7,740 Added 20.63%
45,253 $321,000
Q1 2022

May 16, 2022

SELL
$5.5 - $9.19 $477,757 - $798,289
-86,865 Reduced 69.84%
37,513 $271,000
Q4 2021

Feb 08, 2022

BUY
$7.67 - $44.59 $680,697 - $3.96 Million
88,748 Added 249.08%
124,378 $1.11 Million
Q3 2021

Nov 15, 2021

SELL
$21.33 - $35.06 $624,307 - $1.03 Million
-29,269 Reduced 45.1%
35,630 $1.25 Million
Q2 2021

Sep 13, 2021

BUY
$19.22 - $59.08 $1.25 Million - $3.83 Million
64,899 New
64,899 $1.39 Million

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $266M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.